ADA 2026: A Rigid Trial Design May Have Confounded Survodutide's Tolerability

研报英文原文证据摘录

ADA 2026: A Rigid Trial Design May Have Confounded Survodutide's Tolerability

is changing participant behavior and expectation during clinical trials. Interestingly, combination

of anti-obesity medications is entering practices faster than we can generate long-term evidence, but what is becoming

more clear is that prescribers are shifting from a weight-centric focus in obesity to organ health. The emergence of

all these phase 3 trials targeting HTN, ASCVD, HFpEF, MASH, OSA, and OA are all testaments to this. And, as we

have already known before, weight loss efficacy is not the only thing dictating adoption—tolerability, personalization

flexibility, and affordability all matter perhaps just as much.

Q&A continued to probe the GLP-1R/GCGR mechanism. Following retatrutide's symposium yesterday, questions were

raised on what the addition of GIP agonism does to efficacy, weight loss, and broader health impacts, but ultimately it

is too difficult to draw conclusions based on independent studies. Furthermore, differences in biased agonism further

make it difficult to truly determine what each targeted component of a drug is doing. In other words, we can't tell just yet

how much glucagon contributed. There is clearly a contribution when looking at preclinical data, and it is impressive that

these results do translate into clinical endpoints. The presenter's best guess is that there is a complicated interaction, but

deciphering any more of the impact here is hard. The differences between male and female results in the SYNCHRONIZE

studies continued to be top of mind. The mechanism differences in sex remain unclear, but it was acknowledged that

this is an area worth pursuing. The audience pointed out that there is much to learn on this topic from bariatric surgery